Clinical trial: the efficacy and safety of oral PF‐03491390, a pancaspase inhibitor – a randomized placebo‐controlled study in patients with chronic hepatitis C

2010104 citationsJournal Articlebronze Open Access

Authors

PF-03491390 significantly reduced serum AST and ALT levels in patients with chronic HCV, and was well tolerated over 12 weeks.

Good health and well-being

Published in: Alimentary Pharmacology & Therapeutics

Volume 31, Issue 9, pp. 969-978

Field-Weighted Citation Impact: 2.36